Scale and Capacity Hovione is rapidly expanding manufacturing capacity, including a new 31,000-square-foot facility in New Jersey that doubles US spray-drying capacity and adds two GMP-ready commercial-scale spray dryers, along with ongoing capacity additions in Ireland and Portugal. This presents opportunities to discuss multi-site partnerships, supply continuity, and capacity guarantees for high-demand APIs and drug products.

Continuous Manufacturing The company is a leader in continuous tableting with upcoming ConsiGma CDC Flex deployments, enabling flexible clinical-to-commercial production. This creates sales potential for customers seeking scalable, cost-efficient, and uninterrupted supply chains across development and commercialization phases.

Integrated Solutions Hovione offers end-to-end support across drug substance, intermediates, and finished drug products, with expertise in spray drying and amorphous solid dispersion. Position opportunities around integrated development-to-commercial pathways and accelerated timelines for complex formulations.

Global Partnerships With a diverse, global team and multiple regional sites (Europe, USA, Asia), Hovione emphasizes collaboration and rapid access to manufacturing capabilities. This supports targeted regional partnerships, co-investment models, and faster capital deployment for client programs.

Financial Scale Reported revenue of over $10B and a strategic investment cycle in the US indicate strong financial health and capacity to undertake large-scale CDMO programs. This positions Hovione as a reliable partner for major, high-volume API and finished-dose projects requiring long-term commitments.